Brett Malchow, MD
Family Medicine · Lincoln, NENPI 1558656967
Payments from drug & device makers
Across 381 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$459
- Novo Nordisk$359
- Amgen$324
- Lilly USA, LLC$291
- Pfizer$278
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,37096%
- Education$2064%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 134 | $1,935 |
| GSK | 51 | $459 |
| Novo Nordisk | 24 | $359 |
| Amgen | 25 | $324 |
| Lilly USA, LLC | 24 | $291 |
| Pfizer | 19 | $278 |
| Abbott | 1 | $200 |
| Bayer | 12 | $166 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $160 |
| Otsuka America Pharmaceutical, Inc. | 7 | $124 |
| AstraZeneca | 2 | $118 |
| Exact Sciences | 7 | $111 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $95 |
| Sanofi-aventis U.S. LLC | 7 | $87 |
| Phathom Pharmaceuticals, Inc. | 3 | $85 |
| Boehringer Ingelheim | 5 | $73 |
| Merck | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 4 | $63 |
| Organon | 3 | $55 |
| Axsome Therapeutics, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Abiomed | 1 | $35 |
| Johnson & Johnson | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Genentech USA, Inc. | 2 | $26 |
| Dexcom, Inc. | 2 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Bausch Health US, LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Gilead | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Lite system$200
- SYMBICORT$112
- FARXIGA$112
How this compares
$5,576 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $132,196 |
| FarxigaDapagliflozin Propanediol | 100 | $76,814 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $71,681 |
| EliquisApixaban | 101 | $57,582 |
| XareltoRivaroxaban | 54 | $41,270 |
| MounjaroTirzepatide | 27 | $27,227 |
| TrulicityDulaglutide | 26 | $24,566 |
| JardianceEmpagliflozin | 22 | $22,587 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $18,445 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $17,463 |
| UbrelvyUbrogepant | 14 | $13,703 |
| JanuviaSitagliptin Phosphate | 18 | $12,512 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $12,000 |
| InvokanaCanagliflozin | 21 | $11,778 |
| MyrbetriqMirabegron | 26 | $11,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $359 | $132,196137 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $118 | $95,259126 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Shingrix, Anoro Ellipta, Breo Ellipta | $459 | $94,593181 claims |
| PfizerEliquis, Premarin | $278 | $63,336113 claims |
| Johnson & JohnsonXarelto, Invokana | $33 | $53,04875 claims |
| Lilly USA, LLCMounjaro, Trulicity | $291 | $51,79453 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $73 | $30,89938 claims |
| AbbVieUbrelvy, Namzaric | $1,935 | $21,04626 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $87 | $17,46320 claims |
| MerckJanuvia | $63 | $12,51218 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $11,05526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Lincoln
- Allen HuntLincoln$17.2M
- Michael IsraelLincoln$375K
- Randy KohlLincoln$67K
- Matthew GlennLincoln$17K
- Uma NookaLincoln$12K
- Kylie ParshallLincoln$12K
- Michael HuffmanLincoln$11K
- Svjetlana DzikoLincoln$11K
- Eric JohnsonLincoln$10K
- Gary van ErtLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.